Drugs / SC-43
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03443622 | May 2021 → Dec 2022 | refractory malignant neoplasm | SupremeCure Pharma Inc. | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04733521 | May 2021 → Sep 2023 | biliary tract cancer, non-small cell lung carcinoma | RaND Biosciences | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SC-43 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03443622 ↗ |
| Known as | 1-\[4-chloro-3(trifluoromethyl)phenyl-3-\[3-(4-cyanophenoxy)\] urea | “SC-43 Oral Solution has drug substance of 1-\[4-chloro-3(trifluoromethyl)phenyl-3-\[3-(4-cyanophenoxy)\] urea, or SC-43.” NCT03443622 ↗ |
| Action | Inhibit | “As a result of STAT3 inhibition by SC-43 treatment, decreased cell viability and enhanced apoptosis have been observed in cancer cells.” NCT03443622 ↗ |
| Modality | Small molecule | — CHEMBL2063215 ↗ |
| Route | Oral | “SC-43 oral, every day of 21-day cycle” NCT04733521 ↗ |
| Target | STAT3 | “SC-43 inhibits tumor growth through the activation of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and the repression of p-STAT3 signalings.” NCT03443622 ↗ |